Adagio Medical Holdings, Inc Common Stock (ADGM) - Net Assets
Based on the latest financial reports, Adagio Medical Holdings, Inc Common Stock (ADGM) has net assets worth $-1.31 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.55 Million) and total liabilities ($32.86 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Adagio Medical Holdings, Inc Common Stoc (ADGM) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.31 Million |
| % of Total Assets | -4.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Adagio Medical Holdings, Inc Common Stock - Net Assets Trend (2020–2024)
This chart illustrates how Adagio Medical Holdings, Inc Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Adagio Medical Holdings, Inc Common Stoc total assets for the complete picture of this company's asset base.
Annual Net Assets for Adagio Medical Holdings, Inc Common Stock (2020–2024)
The table below shows the annual net assets of Adagio Medical Holdings, Inc Common Stock from 2020 to 2024. For live valuation and market cap data, see how much is Adagio Medical Holdings, Inc Common Stoc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $19.91 Million | +115.08% |
| 2023-12-31 | $-132.02 Million | -37.70% |
| 2022-12-31 | $-95.88 Million | -32.03% |
| 2021-12-31 | $-72.62 Million | -536261.62% |
| 2020-12-31 | $-13.54K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Adagio Medical Holdings, Inc Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7057246100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.01% |
| Other Comprehensive Income | $1.00K | 0.01% |
| Other Components | $90.50 Million | 454.47% |
| Total Equity | $19.91 Million | 100.00% |
Adagio Medical Holdings, Inc Common Stock Competitors by Market Cap
The table below lists competitors of Adagio Medical Holdings, Inc Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rubean AG
F:R1B
|
$21.60 Million |
|
Gillanders Arbuthnot & Company Limited
NSE:GILLANDERS
|
$21.62 Million |
|
Elevation Oncology Inc
NASDAQ:ELEV
|
$21.63 Million |
|
Archtis Ltd
AU:AR9
|
$21.63 Million |
|
Nyesa Valores Corp SA
MC:NYE
|
$21.59 Million |
|
Ocean Vantage Holdings Bhd
KLSE:0220
|
$21.59 Million |
|
MIND CTI Ltd
NASDAQ:MNDO
|
$21.59 Million |
|
NanoViricides Inc
NYSE MKT:NNVC
|
$21.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Adagio Medical Holdings, Inc Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -132,023,000 to 19,912,000, a change of 151,935,000.
- Net loss of 53,763,000 reduced equity.
- Other comprehensive income decreased equity by 16,000.
- Other factors increased equity by 205,714,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-53.76 Million | -270.0% |
| Other Comprehensive Income | $-16.00K | -0.08% |
| Other Changes | $205.71 Million | +1033.12% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Adagio Medical Holdings, Inc Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $0.00 | $1.03 | x |
| 2021-12-31 | $-3.78 | $1.03 | x |
| 2022-12-31 | $-5.00 | $1.03 | x |
| 2023-12-31 | $-16.81 | $1.03 | x |
| 2024-12-31 | $1.31 | $1.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Adagio Medical Holdings, Inc Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -270.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -19986.25%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 2.43x
- Recent ROE (-270.00%) is below the historical average (-54.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-12.19K |
| 2021 | 0.00% | -7384.44% | 0.01x | 0.00x | $-12.68 Million |
| 2022 | 0.00% | -12525.40% | 0.02x | 0.00x | $-14.09 Million |
| 2023 | 0.00% | -12715.33% | 0.04x | 0.00x | $-24.94 Million |
| 2024 | -270.00% | -19986.25% | 0.01x | 2.43x | $-55.75 Million |
Industry Comparison
This section compares Adagio Medical Holdings, Inc Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,703,112,494
- Average return on equity (ROE) among peers: -82.55%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-1.31 Million | 0.00% | N/A | $21.60 Million |
| Abbott Laboratories (ABT) | $24.16 Billion | 9.46% | 0.81x | $155.56 Billion |
| Aethlon Medical Inc (AEMD) | $9.29 Million | -84.45% | 0.15x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $105.73 Million | -116.68% | 0.61x | $903.35K |
| Adapthealth Corp (AHCO) | $15.14 Million | -140.98% | 14.05x | $1.39 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $2.15 Million | -112.84% | 0.45x | $16.04 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $8.60 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $644.00K | -309.01% | 0.34x | $4.22 Million |
| Artivion Inc (AORT) | $89.39 Million | 8.74% | 0.25x | $1.73 Billion |
| Apyx Medical Inc (APYX) | $21.15 Million | 2.82% | 0.30x | $125.55 Million |
About Adagio Medical Holdings, Inc Common Stock
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablat… Read more